Biohaven Ltd. (NYSE:BHVN) Shares Bought by Algert Global LLC

Algert Global LLC grew its position in Biohaven Ltd. (NYSE:BHVN) by 337.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,392 shares of the company’s stock after acquiring an additional 24,990 shares during the period. Algert Global LLC’s holdings in Biohaven were worth $1,619,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. KBC Group NV boosted its holdings in Biohaven by 24.5% in the 3rd quarter. KBC Group NV now owns 2,250 shares of the company’s stock valued at $112,000 after purchasing an additional 443 shares in the last quarter. Hsbc Holdings PLC grew its holdings in Biohaven by 6.1% during the second quarter. Hsbc Holdings PLC now owns 8,291 shares of the company’s stock worth $286,000 after acquiring an additional 480 shares during the period. Canton Hathaway LLC raised its position in Biohaven by 2.3% in the second quarter. Canton Hathaway LLC now owns 21,850 shares of the company’s stock worth $758,000 after acquiring an additional 500 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in Biohaven by 19.1% in the third quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company’s stock valued at $156,000 after acquiring an additional 500 shares during the period. Finally, Arizona State Retirement System boosted its position in shares of Biohaven by 3.7% during the 2nd quarter. Arizona State Retirement System now owns 20,575 shares of the company’s stock worth $714,000 after purchasing an additional 730 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Biohaven

In other news, Director Gregory Bailey acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The shares were bought at an average cost of $44.19 per share, for a total transaction of $220,950.00. Following the acquisition, the director now directly owns 1,620,071 shares in the company, valued at $71,590,937.49. This trade represents a 0.31 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John W. Childs bought 21,052 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were purchased at an average price of $47.50 per share, with a total value of $999,970.00. Following the acquisition, the director now directly owns 21,052 shares in the company, valued at approximately $999,970. This trade represents a ? increase in their position. The disclosure for this purchase can be found here. 16.00% of the stock is owned by company insiders.

Biohaven Stock Performance

Shares of NYSE BHVN opened at $46.38 on Thursday. Biohaven Ltd. has a 1 year low of $26.80 and a 1 year high of $62.21. The firm’s 50 day moving average price is $49.39 and its 200 day moving average price is $41.21. The firm has a market cap of $4.69 billion, a P/E ratio of -5.06 and a beta of 1.31.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.03). As a group, equities analysts predict that Biohaven Ltd. will post -8.85 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Jefferies Financial Group started coverage on shares of Biohaven in a research note on Monday, September 16th. They issued a “buy” rating and a $57.00 price objective for the company. TD Cowen upped their price target on Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price objective on Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a report on Thursday, October 3rd. Royal Bank of Canada lowered their target price on Biohaven from $66.00 to $58.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Robert W. Baird lifted their price target on Biohaven from $58.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, September 23rd. Thirteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Biohaven currently has an average rating of “Buy” and an average target price of $62.75.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.